1453P - Solitary Fibrous Tumor (SFT): A Registry Program to assess frequency and managemente in our country. A Spanish Group for Research on Sarcoma (GEIS)...

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Soft Tissue Sarcomas
Aetiology, Epidemiology, Screening and Prevention
Basic Scientific Principles
Presenter Josefina Cruz Jurado
Citation Annals of Oncology (2014) 25 (suppl_4): iv494-iv510. 10.1093/annonc/mdu354
Authors J. Cruz Jurado1, C. Valverde Morales2, M.A. Vaz3, R. Alvarez Alvarez4, A. Lopez Pousa5, P. Sancho Marquez6, J.A. Carrasco7, J. Martinez-Trufero8, M.A. Sala Gonzalez9, J.L. Arranz10, L.M. De Sande González11, M.J. Blanco Sanchez12, C. Orbegoso13, J.A. Pérez-Fidalgo14, J. Martinez García15, J. Lavernia16, I. Sevilla17, J.M. Cano18, A. Meana19, J. Martin Broto20
  • 1Medical Oncolgy, Hospital Universitario Canarias, 38320 - Tenerife/ES
  • 2Medical Oncology, Hospital Vall d´hebrón, barcelona/ES
  • 3Medical Oncology, Ramon y Cajal, madrid/ES
  • 4Medical Oncology, hospital gregorio marañon, madrid/ES
  • 5Medical Oncology, Hospital de la Santa Creu i Sant Pau, barcelona/ES
  • 6Medical Oncology, Hospital Virgen del Rocio, sevilla/ES
  • 7Medical Oncolgy, Hospital Xeral Cies, vigo/ES
  • 8Medical Oncology, H U Miguel Servet, zaragoza/ES
  • 9Medical Oncology, Hospital de Basurto, basurto/ES
  • 10Medical Oncology, Fundación Jimenez Diaz, Madrid/ES
  • 11Medical Oncology, Complejo Hospitalario de León, León/ES
  • 12Medical Oncology, Hospital Dr Negrín, Las Palmas/ES
  • 13Medical Oncology, Hospital Marqués de Valdecilla, santander/ES
  • 14Medical Oncology, H Clinico Universitario de Valencia, valencia/ES
  • 15Medical Oncology, Hospital Virgen de la Arrixaca, Murcia/ES
  • 16Medical Oncology, Instituto Valenciano de Oncologia, valencia/ES
  • 17Medical Oncology, C U Virgen de la Victoria, málaga/ES
  • 18Medical Oncology, H. General Ciudad Real, ciudad real/ES
  • 19Medical Oncology, U G U D´Alacant, alicante/ES
  • 20Medical Oncology, Hospital Son Espasses, Mallorca/ES



SFT are soft tissue sarcomas with low incidence and intermediate biological potential behavior. The main aim of this observational study is to get new insights in clinical presentation, biological behavior and therapeutic approaches of SFT in our country.


A web-based registry was built to collect diagnostic and therapeutic processes in patients (p) with SFT diagnosed in 22 centers (centers of reference and secondary centers) involved in this program. Median progression-free survival (PFS) and overall survival (OS), were estimated by Kaplan-Meier method. Ethics committee approval was obtained.


Between September 1999 and November 2013, 163 p (median age 52 years, 52.8% females, 88% had Karnofsky≥80%) were diagnosed. 12 p lacked some relevant data after diagnosis. 7 hospitals included 70% of cases. Primary tumor location was: 24% extremities and trunk-wall, 15% lungs, 13% pleural, 13% head and neck, 14% retroperitoneum and 2.5% meningeal sites. Excisional biopsy and core-biopsy were the method of diagnosis in 65% and 22% of p respectively. Median size was 8.6 cm (range 1-29). 11 p were metastatic at diagnosis. Initial treatment was surgery in 89% of 151 p, followed by adjuvant treatment in 23: 2 chemotherapy (CT), 15 radiotherapy (RT), 5 CT and RT, and 1 radiosurgery. The remaining p received: 1 CT, 2 RT, 1 sunitinib and 2 palliative care. 36 p progressed: 19 p could be resected. Antiangiogenic therapy was used in advanced disease:13 p received sunitinib (5 first line, 3 second line and 5 further lines), 5 p temozolamide-bevacizumab (3 first line and 2 further lines) and 2 p pazopanib (1 first line) . Sunitinib showed clinical benefit (CB) in 8 cases (35, 36, 30, 22, 8, 5, 4 and 2 months of duration), 4 progressions (PR) and 1 unknown. 2 p stopped for toxicity grade III-IV. Temozolamide-bevacizumab experienced CB in 3 cases (30,12, and 6 months of duration), 1 PR and 1 p stopped for toxicity grade III. 1p progressed with pazopanib and 1 was not evaluated for response. Median PFS was 5 years and median OS was not reached. OS and PFS at 10 years were 70% and 50% respectively.


SFT are tumors that appear in different localizations, where radical surgery is the treatment of choice. In advanced disease, antiangiogenic therapy could provide longer CB in 60% of progressing cases. Studies with these drugs in advanced SFT are guaranteed.


All authors have declared no conflicts of interest.